Abstract
The incidence of acute otitis media (AOM) in infants and young children has increased dramatically in recent years in the United States. AOM often follows upper respiratory tract infections due to pathogens such as respiratory syncytial virus (RSV), influenza virus, and parainfluenza virus (PIV). These viruses cause eustachian tube dysfunction that is critical to the pathogenesis of AOM. Vaccines against these viruses would likely reduce the incidence of AOM. In three previous studies, influenza virus vaccines reduced the incidence of AOM by 30% to 36%. Vaccines to prevent infections with RSV and PIV type 3 are undergoing clinical testing at this time. Streptococcus pneumoniae, nontypeable Haemophilus influenzae (NTHi), and Moraxella catarrhalis are the three most common AOM pathogens. Heptavalent pneumococcal conjugate vaccine is effective in preventing invasive disease and AOM caused by serotypes contained in the vaccine. Vaccine candidates for NTHi and M. catarrhalis are under development.
Article PDF
Similar content being viewed by others
References and Recommended Reading
Freid VM, Makuc DM, Rooks RN: Ambulatory health care visits by children: principal diagnosis and place of visit. Hyattsville: Centers for Disease Control and Prevention/National Center for Health Statistics; 1998. [Vital and Health Statistics 13:1-23.]
Schappert SM: Office visits for otitis media: United States, 1975–90. Hyattsville: Centers for Disease Control and Prevention/National Center for Health Statistics; 1992. [Vital and Health Statistics Adv Data 214:1-18.]
Daly KA, Hunter LL, Giebink GS: Chronic otitis media with effusion. Pediatr Rev 1999, 20:85–93.
Gates GA: Cost-effectiveness considerations in otitis media treatment. Otolaryngol Head Neck Surg 1996, 114:525–530.
Paradise JL, Rockette HE, Colborn K, et al.: Otitis media in 2253 Pittsburgh-area infants: prevalence and risk factors during the first two years of life. Pediatrics 1997, 99:318–333.
Teele DW, Klein JO, Rosner B: Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 1989, 160:83–94.
Lim DJ, Chun YM, Lee HY, et al.: Cell biology of tubotympanum in relation to pathogenesis of otitis media - a review. Vaccine 2001, 19:S17-S25.
Rynnel-Dagoo B, Agren K: The nasopharynx and the middle ear: inflammatory reactions in middle ear disease. Vaccine 2001, 19:S26-S31.
Giebink GS, Ripley ML, Wright PF: Eustachian tube histopathology during experimental influenza A virus infection in the chinchilla. Ann Otol Rhinol Laryngol 1987, 96:199–206.
Sanyal MA, Henderson FW, Stempel EC, et al.: Effect of upper respiratory tract infection on eustachian tube ventilatory function in the preschool child. J Pediatr 1980, 97:11–15.
Heikkinen T: Role of viruses in the pathogenesis of acute otitis media. Pediatr Infect Dis J 2000, 19:S17-S23.
Heikkinen T, Ruuskanen O: Temporal development of acute otitis media during upper respiratory tract infection. Pediatr Infect Dis J 1994, 13:659–661.
Ruuskanen O, Arola M, Putto-Laurila A, et al.: Acute otitis media and respiratory virus infections. Pediatr Infect Dis J 1989, 8:94–99.
Heikkinen T, Thint M, Chonmaitree T: Prevalence of various respiratory viruses in the middle ear during acute otitis media. N Engl J Med 1999, 340:260–264. Using culture and antigen detection techniques, the investigators found RSV in the middle ear fluid of 74% of children in whom the same virus was found in nasopharyngeal secretions, PIV in 52%, and influenza virus in 42%.
Pitkaranta A, Virolainen A, Jero J, et al.: Detection of rhinovirus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction. Pediatrics 1998, 102:291–295. These investigators used RT-PCR to detect rhinovirus RNA in the middle ear fluid of 64% of children with the same virus in their nasopharyngeal secretions, RSV in 57%, and coronavirus in 36%.
Heikkinen T, Ruuskanen O, Waris M, et al.: Influenza vaccination in the prevention of acute otitis media in children. Am J Dis Child 1991, 145:445–448.
Clements DA, Langdon L, Bland C, Emmanuel W: Influenza A vaccine decreases incidence of otitis media in 6- to 30- month-old children in day care. Arch Pediatr Adolesc Med 1995, 149:1113–1117.
Belshe RB, Mendelman PM, Treanor J, et al.: The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998, 338:1405–1412. A novel trivalent, live attenuated, intranasal influenza vaccine was 93% efficacious against culture-positive influenza and resulted in 30% fewer episodes of febrile AOM.
Hoberman A, Greenberg DP, Paradise JL, et al.: Efficacy of influenza vaccine in the prevention of acute otitis media (AOM) [abstract]. Pediatr Res 2001, in press.
Simoes EAF, Groothuis JR, Tristram DA, et al.: Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high-risk children. J Pediatr 1996, 129:214–219.
Karron RA, Wright PF, Crowe JE Jr, et al.: Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis 1997, 176:1428–1436.
Wright PF, Karron RA, Crowe JE Jr, et al.: Evaluation of a live, attenuated respiratory syncytial virus (RSV) vaccine candidate, cpts 248/404, in infancy. Pediatr Res 1998, 43:161A.
Collins PL, Whitehead SS, Bukreyev A, et al.: Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv Virus Res 1999, 54:423–451.
Tristram DA, Welliver RC, Mohar CK, et al.: Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18–36 months old. J Infect Dis 1993, 167:191–195.
Belshe RB, Anderson EL, Walsh EE: Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis 1993, 168:1024–1029.
Groothuis JR, King SJ, Hogerman DA, et al.: Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronochopulmonary dysplasia. J Infect Dis 1998, 177:467–469.
Piedra PA, Grace S, Jewell A, et al.: Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J 1996, 15:23–31.
Falsey AR, Walsh EE: Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 1997, 15:1130–1132.
Belshe RB, Karron RA, Newman FK, et al.: Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children. J Clin Microbiol 1992, 30:2064–2070.
Karron RA, Wright PF, Newman FK, et al.: A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J Infect Dis 1995, 172:1445–1450.
Karron RA, Wright PF, Hall SL, et al.: A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic and phenotypically stable in infants and children. J Infect Dis 1995, 171:1107–1114.
Karron RA, Makhene M, Gay K, et al.: Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants. Pediatr Infect Dis J 1996, 15:650–654.
Greenberg DP, Yeh S, Yogev R, et al.: Evaluation of the safety, immunogenicity and virus shedding of an intranasal live attenuated bovine parainfluenza virus type 3 vaccine in infants. Pediatr Res 1999, 45:161A.
American Academy of Pediatrics: Recommended childhood immunization schedule—United States, January-December 2001. Pediatrics 2001, 107:202.
Zenni MK, Cheatham SH, Thompson JM, et al.: Streptococcus pneumoniae colonization in the young child: association with otitis media and resistance to penicillin. J Pediatr 1995, 127:533–537.
Dagan R, Muallem M, Melamed R, et al.: Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr Infect Dis J 1997, 16:1060–1064.
Black S, Shinefield H, Fireman B, et al.: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000, 19:187–195. In this double-blind, randomized, placebo-controlled trial of 37,868 children, heptavalent PCV was 93.9% efficacious against invasive pneumococcal infections caused by vaccine serotypes. The vaccine reduced the incidence of all episodes of AOM by 6.4%, visits for AOM by 7.8%, and the need for ventilatory tube placement by 20.3%.
Eskola J, Kilpi T, Palmu A, et al.: Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001, 344:403–409. In this double-blind, randomized, placebo-controlled trial of 1662 children, heptavalent PCV reduced the incidence of all causes of AOM by 6%, all pneumococcal AOM by 34%, and AOM caused by vaccine serotypes by 57%.
Mbelle N, Huebner RE, Wasas AD, et al.: Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999, 180:1171–1176.
Briles DE, Hollingshead SK, Nabors GS, et al.: The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine 2001, 19:S87-S95.
White P, Hermansson A, Svanborg C, et al.: Effects of active immunization with a pneumococcal surface protein (PspA) and of locally applied antibodies in experimental otitis media. ORL J Otorhinolaryngol Relat Spec 1999, 61:206–211.
Nabors GS, Braun PA, Herrmann DJ, et al.: Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly crossreactive antibodies to heterologous PspA molecules. Vaccine 2000, 18:1743–1754.
Foxwell RA, Kyd JM, Cripps AW: Nontypeable Haemophilus influenzae: pathogenesis and prevention. Microbiol Mol Biol Rev 1998, 62:294–308.
Kyd JM, Dunkley ML, Cripps AW: Enhanced respiratory clearance of nontypeable Haemophilus influenzae following mucosal immunization with P6 in a rat model. Infect Immun 1995, 63:2931–2940.
Yamanaka N, Faden H: Antibody response to outer membrane protein of nontypeable Haemophilus influenzae in otitisprone children. J Pediatr 1993, 122:212–218.
Bakaletz LO, Kennedy BJ, Novotny LA, et al.: Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection. Infect Immun 1999, 67:2746–2762.
Giebink GS: Vaccination against middle-ear bacterial and viral pathogens. Ann N Y Acad Sci 1997, 830:330–352.
Kyd J, John A, Cripps A, Murphy TF: Investigation of mucosal immunisation in pulmonary clearance of Moraxella (Branhamella) catarrhalis. Vaccine 2000, 18:398–406.
McMichael JC: Vaccines for Moraxella catarrhalis. Vaccine 2001, 19:S101-S107.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Greenberg, D.P., Hoberman, A. Vaccine prevention of acute otitis media. Curr Allergy Asthma Rep 1, 358–363 (2001). https://doi.org/10.1007/s11882-001-0049-8
Issue Date:
DOI: https://doi.org/10.1007/s11882-001-0049-8